Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,349,618
-$1,667,428 QoQ
Shares Held
166,980
+2.4% QoQ
Ownership
0.716%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GEODE CAPITAL MANAGEMENT, LLC holds $18,583,356,554 across 528 Biotechnology names. LYEL ranks #236 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,139,621 | $2,741,586,360 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,607,732 | $2,014,838,051 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,660,385 | $880,241,584 | |
| 4 | INSM |
INSMED Inc
|
4,450,389 | $727,727,608 | |
| 5 | MRNA |
Moderna, Inc.
|
9,435,132 | $479,304,705 | |
| 6 | INCY |
Incyte Corp
|
4,703,184 | $442,663,677 | |
| 7 | RPRX |
Royalty Pharma plc
|
7,869,632 | $377,506,246 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
4,918,030 | $365,212,906 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,349,618 | 166,980 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $5,017,046 | 162,997 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $2,115,373 | 130,257 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $912,906 | 103,270 | Shares | Defined | 2025-08-08 | |
| No filing history on record for this holder in this stock. | ||||||